Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 3, Pages e91139
Publisher
Public Library of Science (PLoS)
Online
2014-03-08
DOI
10.1371/journal.pone.0091139
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prognostic significance and targeting of HER family in colorectal cancer
- (2013) Helmout Modjtahedi Frontiers in Bioscience-Landmark
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
- (2012) S. Stintzing et al. ANNALS OF ONCOLOGY
- Therapeutic application of monoclonal antibodies in cancer: advances and challenges
- (2012) H. Modjtahedi et al. BRITISH MEDICAL BULLETIN
- Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients
- (2012) Robert Königsberg et al. ONCOLOGY
- An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
- (2011) Edward Chu Clinical Colorectal Cancer
- The Role of HER-3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab
- (2011) M. Scartozzi et al. ONCOLOGIST
- Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer
- (2010) J. R. Hecht et al. CLINICAL CANCER RESEARCH
- Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
- (2009) Helmout Modjtahedi et al. ANTI-CANCER DRUGS
- The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer
- (2009) Emmet McIntyre et al. BREAST CANCER RESEARCH AND TREATMENT
- ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery
- (2009) Glauco Baiocchi et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- (2009) Salvatore Siena et al. JNCI-Journal of the National Cancer Institute
- Clinical utility of type 1 growth factor receptor expression in colon cancer
- (2008) Sher-Ping Leung et al. AMERICAN JOURNAL OF SURGERY
- U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens
- (2008) R. M. Giusti et al. CLINICAL CANCER RESEARCH
- Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer
- (2008) Mei Wu et al. CLINICAL THERAPEUTICS
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started